<DOC>
	<DOCNO>NCT00003113</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness oral combination chemotherapy G-CSF elderly patient intermediate- high-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Oral Combination Chemotherapy Treating Elderly Patients With Intermediate High-Grade Non-Hodgkin 's Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : - Assess feasibility toxicity oral combination chemotherapy granulocyte colony-stimulating factor elderly patient intermediate high grade non-Hodgkin 's lymphoma . - Determine objective response rate , response duration , survival patient population . OUTLINE : All patient receive one cycle oral chemotherapy , 6 week duration . Etoposide give day 1-3 cyclophosphamide procarbazine give day 22-31 cycle . Lomustine give day 1 cycle 1 3 . Filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) give subcutaneously day 5-21 33-42 cycle . Patients disease progression one cycle therapy time thereafter take study . Patients complete response 1 cycle therapy receive 2 additional cycle chemotherapy observed treatment . Patients partial response ( PR ) also receive 2 additional cycle chemotherapy . Following third cycle chemotherapy , residual disease confine 1 2 nodal site , patient receive radiation therapy . All patient PR treat investigator 's discretion . Patients follow every 3 month death . PROJECTED ACCRUAL : A maximum 32 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven stage I IV intermediate high grade nonHodgkin 's lymphoma Bcell , Tcell , indeterminate immunologic phenotype Measurable evaluable No cytologic radiographic evidence CNS lymphoma PATIENT CHARACTERISTICS : Age : 60 Performance status : ECOG 03 Life expectancy : At least 6 week Hematopoietic : WBC least 1500/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 3.0 mg/dL Renal : Creatinine great 3.0 mg/dL PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow localized stage I II disease progress beyond initial radiotherapy port Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage II mantle cell lymphoma</keyword>
</DOC>